USSTOCK.TODAY
Market Closed
Log in Sign up

Zenmap confirms 50% reduction in death risk in first-line head and neck squamous cell carcinoma clinical trial

Clinical Trials Arena · ·by G4L

GMAB Genmab ADR
$54.07 -3.10%
View chart & analysis →
  1. 1The Phase 3 clinical trial confirmed a 50% reduction in death risk for Zenmap's combination therapy of petocesanatab and Keytruda.
  2. 2The first interim analysis showed an odds ratio of 3.17 for the objective response rate (ORR) of the Zenmap combination therapy.
  3. 3Zenmap (Nasdaq) shares rose 28.25% from the closing price on October 27 to the closing price on October 28.

So what's the key point?

Zenmap reduced the risk of death by 50% in a trial for combined cancer treatment. Following this news, Zenmap shares listed on the Nasdaq rose 28.25%.

Source Clinical Trials Arena · View original ↗

Related 3-line summaries

Genmab reports 22% increase in total revenue for first nine months of 2026 The Motley Fool +1 · 3d agoGenmab shares surge 13% following announcement of colorectal cancer treatment clinical results Investing.com · Oct 26Genmab shares rise 9% on positive Phase 3 clinical trial results for ovarian cancer treatment Investing.com +1 · Oct 24
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news